Neostig (Neostigmine Methylsulfate)

Neostigmine methylsulfate, the active ingredient in Neostig, is an acetylcholinesterase inhibitor presented as a sterile injectable solution for intramuscular, intravenous, and subcutaneous use. It is employed to manage myasthenia gravis, reverse non‑depolarizing neuromuscular blockade, and treat postoperative ileus. GNH USA supplies Neostig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neostig acts on the cholinergic neuromuscular pathway and is indicated for several clinical conditions.

Myasthenia gravis: improves skeletal muscle strength by enhancing neuromuscular transmission. Reversal of non‑depolarizing neuromuscular blockade: restores muscle function after surgery. Postoperative ileus: stimulates gastrointestinal motility to reduce ileus duration.

Neostig may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Muscle cramps or fasciculations - Excessive salivation or sweating - Nausea or vomiting - Diarrhea or abdominal cramping - Flushing or headache - Dizziness or visual disturbances

Serious or Rare Side Effects: - Bradycardia or heart block - Bronchospasm or severe respiratory distress - Profound hypotension - Cholinergic crisis with muscle weakness and respiratory failure - Seizures or convulsions - Anaphylactic reactions

Before using Neostig, consider the following safety measures.

Renal impairment: adjust dose or monitor plasma levels closely. Asthma or COPD: may precipitate bronchospasm; monitor respiratory status. Cardiac disease: observe heart rate and rhythm for bradyarrhythmias. Pregnancy: use only if potential benefit justifies potential risk to the fetus. Concomitant cholinesterase inhibitors: avoid additive cholinergic effects. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neostig can interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Other cholinesterase inhibitors: additive cholinergic toxicity. - Beta‑blockers: may exacerbate bradycardia. - Magnesium sulfate: potentiates neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish therapeutic effect. - Inhaled anesthetics (e.g., sevoflurane): may enhance cholinergic response. - Non‑depolarizing neuromuscular blockers: may require dose adjustment.